YIH
LYEL icon

Y-Intercept (HK)’s Lyell Immunopharma LYEL Stock Holding History

Y-Intercept (HK)’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,439
Closed -$94.6K – 1596
2023
Q4 		$94.6K Buy
+2,439
New +$87.8K 0.01% 1096

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Y-Intercept (HK)'s LYEL Position: Q1 2024 in Review

Y-Intercept (HK) sold out of Lyell Immunopharma (LYEL) in Q1 2024, closing a stake of 2,439 shares — an estimated $94.6K sold.

Y-Intercept (HK) first reported a position in LYEL in Q4 2023 and held it in 1 quarter. The position peaked at $94.6K in Q4 2023. 127 funds tracked by Wall St. Rank hold LYEL as of Q1 2024.

  • Y-Intercept (HK) reported no remaining Lyell Immunopharma position as of Q1 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 2,439 Lyell Immunopharma shares in Q1 2024, an estimated $94.6K.
  • Y-Intercept (HK) first reported a position in Lyell Immunopharma in Q4 2023 and held it in 1 quarter.
  • Y-Intercept (HK)'s Lyell Immunopharma position peaked at $94.6K in Q4 2023.
  • 127 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2024.

Based on Y-Intercept (HK)'s 13F filing for Q1 2024, filed 10 May 2024.